TS inhibitors (5-fluorourocil (5-FU) and tomudex (TDX)) block TS activity and have been effectively used in the treatment of human solid tumours such as colorectal, breast and lung cancers (Burris et al, 1994; Cunningham et al, 1994; Smith et al, 2002). Here, TYMS is linked to lung cancer.